Johnson & Johnson (JNJ) Other Non-Current Assets (2009 - 2026)
Johnson & Johnson (JNJ) posted Other Non-Current Assets of $14.3 billion for Q2 2026, up 1.16% sequentially from $14.1 billion in Q1 2026, and up 17.06% YoY from $12.2 billion in Q2 2025.
Johnson & Johnson (JNJ) Other Non-Current Assets (2009 - 2026) Analysis & Trends
Johnson & Johnson has reported Other Non-Current Assets for 18 years, with the latest figure at $14.3 billion in Q2 2026.
- Quarterly Other Non-Current Assets rose 17.06% year-over-year to $14.3 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $14.3 billion (up 17.06% YoY) and the FY2025 annual result came in at $14.4 billion, up 25.88% from the prior year.
- Other Non-Current Assets rose to $14.3 billion in Q2 2026 per JNJ's latest filing, from $14.1 billion in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $27.2 billion in Q1 2023 and troughed at $8.6 billion in Q4 2022.
- A 5-year average of $12.5 billion and a median of $11.5 billion in 2025 frame the typical range for Other Non-Current Assets.
- The widest YoY moves for Other Non-Current Assets: up 166.61% in 2023, down 48.04% in 2023.
- Over 5 years, Other Non-Current Assets stood at $8.6 billion in 2022, then jumped by 64.09% to $14.2 billion in 2023, then decreased by 19.35% to $11.4 billion in 2024, then rose by 25.88% to $14.4 billion in 2025, then declined by 0.69% to $14.3 billion in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $14.3 billion, $14.1 billion, and $14.4 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 14.27 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 10.73 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 19.60 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 5.93 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 12.98 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 4.75 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 9.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 3.56 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 5.50 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 14.27 Bn |
| Mar 29, 2026 | 14.11 Bn |
| Dec 28, 2025 | 14.37 Bn |
| Sep 28, 2025 | 12.42 Bn |
| Jun 29, 2025 | 12.19 Bn |
| Mar 30, 2025 | 11.53 Bn |
| Dec 29, 2024 | 11.41 Bn |
| Sep 29, 2024 | 10.92 Bn |
| Jun 30, 2024 | 10.54 Bn |
| Mar 31, 2024 | 14.13 Bn |
| Dec 31, 2023 | 14.15 Bn |
| Oct 1, 2023 | 13.13 Bn |
| Jul 2, 2023 | 10.08 Bn |
| Apr 2, 2023 | 9.57 Bn |
| Jan 1, 2023 | 27.24 Bn |
| Oct 2, 2022 | 8.63 Bn |
| Jul 3, 2022 | 9.44 Bn |
| Apr 3, 2022 | 9.94 Bn |
| Jan 2, 2022 | 10.22 Bn |
| Oct 3, 2021 | 6.87 Bn |